Definitive Healthcare acquires HIMSS Analytics data products and services

Healthcare IT News | January 16, 2019

Definitive Healthcare on Wednesday announced that it has acquired HIMSS Analytics' Logic, Predict and Analyze assets to enhance its market intelligence platform. HIMSS Analytics, a Healthcare IT News sister, will continue its focus on maturity models, such as the EMR Adoption Model, and adoption models for analytics, continuity of care and infrastructure. Definitive CEO Jason Krantz said in a statement that combining HIMSS Analytics' data set, which includes information about health IT products hospitals and facilities have installed and purchasing contracts, with Definitive's data about healthcare providers will enhance its market intelligence platform for the newly-combined client base.

Spotlight

Telehealth is transforming the way people receive health care across the United States. With recent advances in broadband coverage and affordable equipment, it is rapidly becoming integrated into primary care, specialty services, and complex health systems. However, many people are still unsure what it is, what quality of care it can provide, and how it could apply to their own health or community.


Other News
HEALTH TECHNOLOGY

MCI Onehealth Partners with MDClone to Accelerate Research through Global Clinical Intelligence Offering

MCI Onehealth Technologies, Inc. | July 29, 2022

MCI Onehealth Technologies Inc. a clinician-led healthcare technology company focused on increasing access to and quality of healthcare, and MDClone, a digital health company and leader in synthetic data, are pleased to announce an advanced clinical intelligence offering for their global partners. This offering combines real-world health insights with mirrored synthetic data to power deeper research and inspire novel therapeutic development. “MCI’s collaboration with MDClone will provide our partners with greater access to high-value data-insights-as-a-service for an array of research, clinical and data science needs. Whether through MCI’s clinic network, international healthcare providers, or pharmaceutical, life sciences and biotech partners, our mutually enhanced insights will help to quickly translate healthcare data and research into improved health and quality of life for patients.” Dr. Alexander Dobranowski, MD, Chief Executive Officer of MCI The real-world patient health journeys that MCI’s tech-enabled network is able to capture offer a comprehensive picture to researchers, who can benefit from a fuller perspective. The partnership between MCI and MDClone will leverage MDClone’s technology to load, organize and protect MCI-generated patient data and use this data to help find insights to improve care. In addition, MCI and MDClone intend to work together to improve data collection and curation to better serve the needs of applied healthcare research. MDClone offers clients robust, detailed data for thorough end-to-end, real-world analysis. Using the MDClone ADAMS Platform analytics tools and synthetic data capabilities, clinicians, researchers, and healthcare professionals can explore healthcare data more efficiently to accelerate real-world evidence processes. With synthetic data capabilities at the forefront, users can leverage self-service tools to access, analyze, and share information without privacy concerns. Additionally, the real-time identification and extraction of information about a specific population of interest allows users at healthcare systems to overcome some of the common barriers that can slow clinical data projects’ progress. “We’re thrilled to partner with innovators like MCI in the healthcare and life science industries and beyond. Together, we can provide tailored clinical insights that meet clients’ needs, and from those insights, MDClone can generate synthetic data that researchers can use to better understand disease progression, enhance care delivery, and develop new products that can improve patient outcomes,” said Josh Rubel, Chief Operating Officer of MDClone. In keeping with its objective to be a preeminent health technology leader, MCI nurtures international opportunities to leverage its vast pool of high-quality structured clinical information. The MDClone ADAMS Platform’s unique ability to convert datasets and cohorts of interest into synthetic files that are statistically comparable to the original data, but composed entirely of artificial patients, aids in broader and more secure access and opens the doors to third-party access and larger-scale research impact. MCI’s audience for health insights continues to grow in Canada and will further benefit from access to MDClone’s global roster of top-tier health system and pharma relationships. The collaboration with MDClone will accelerate MCI’s entry into the clinical insights and analytics sectors in the United States of America and Israel, including potential access to headquarter-level decision-makers of global pharma and life science leaders. “Through this commercial arrangement, we each have the benefit of immediate introduction to the active client rosters of the other, and we each gain a superior — and unique — offering to acquire new partners, fueling the expansion of MCI’s health insight services into international markets,” added Dr. Dobranowski. About MCI MCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs. As part of the healthcare community for over 30 years, MCI operates one of Canada’s leading primary care networks with nearly 260 physicians and specialists, serves more than one million patients annually and had nearly 300,000 telehealth visits last year, including online visits via mciconnect.ca. MCI additionally offers an expanding suite of occupational health service offerings that support a growing list of nearly 600 corporate customers. Led by a proven management team of doctors and experienced executives, MCI remains focused on executing a strategy centered around acquiring technology and health services that complement the company’s current roadmap. About MDClone MDClone offers an innovative, self-service data analytics environment powering exploration, discovery, and collaboration throughout healthcare ecosystems cross-institutionally and globally. The powerful underlying infrastructure of the MDClone ADAMS Platform allows users to overcome common barriers in healthcare in order to organize, access, and protect the privacy of patient data while accelerating research, improving operations and quality, and driving innovation to deliver better patient outcomes. Founded in Israel in 2016, MDClone serves major health systems, payers, and life science customers in the United States, Canada, and Israel.

Read More

FUTURE OF HEALTHCARE

Dalrada Accelerates Its National Healthcare Model With Acquisition of Watson Rx Solutions

Dalrada Corporation | June 09, 2022

Dalrada Corporation announced that it had acquired the pharmacy, Watson Rx Solutions, Inc. The move highlights Dalrada’s aggressive growth plans within the healthcare sector and paves the way for a total end-to-end total healthcare solution. Adding the 10-year-old pharmacy to Dalrada Health’s comprehensive model expands the subsidiary’s synergies with potential opportunities across its products and services portfolio and offers another solution to meet patient requirements. Dalrada envisions a comprehensive healthcare solution for all Dalrada Health clients with unique offerings that will now include: a pharmacy to facilitate prescription processing, physicians and clinicians at treatment clinics, expanding into telemedicine, engagement of Dalrada-owned testing facilities and laboratories, and utilization of Company-specific technologies to facilitate immediate growth of the business. “Watson Rx has a long history of providing excellent pharmacy services. This acquisition allows Dalrada to expand its healthcare footprint and continue to build a total health management solution on an already successful turnkey operation. As a result, the Company will be able to successfully address the health needs of even more patients.” CEO and Founder, Brian Bonar Through comprehensive prescription management, education, nursing, and total health management, Watson Rx Solutions' leadership team holds more than six decades of combined experience in various complex pharmacy disease states and retail services, always putting patients first. Dalrada plans on entering the pharmaceutical space with an accelerated strategic plan to leverage the Company’s existing capabilities. Research reveals that the U.S. online and mail-order sales of drugs, health, and beauty aids were valued at 75.5 billion USD in 2020. Additionally, E-commerce pharmaceutical sales and beauty aids increased from 51.7 billion USD the year prior. Online, E-commerce, and mail-order sales increased from around 31 to 38 percent during the same period. Pharmacy and drug store sales reached 300 billion USD in 2020, with over-the-counter (OTC) medication accounting for over 36 billion USD in sales during the same year, the highest-selling year to date for the OTC segment. Dalrada and its subsidiaries provide value by making timely and impactful products and services available within health, technology, and clean energy markets. About Dalrada Dalrada Corporation drives innovation that positively impacts people, businesses, and the planet. With subsidiaries that are firmly positioned in the world’s top three-growing industries of healthcare, clean energy, and technology, Dalrada creates solutions that are sustainable, affordable, and accessible. The company works continually to produce disruptive products and services that accelerate positive change for current and future generations. Dalrada’s global solutions directly address climate change, post-pandemic gaps in the healthcare industry, and technology solutions for a new era of human behavior and interaction, ensuring a bright future for the world around us.

Read More

FUTURE OF HEALTHCARE

Spectrum Science Acquires The Seismic Collaborative, Deepening Expertise in Emerging Innovation and Health Technology

Spectrum Science | June 10, 2022

Spectrum Science, an independent, integrated marketing, communications and media agency hyper-focused on health and science, announced the acquisition of The Seismic Collaborative, an independent health and life science agency that specializes in supporting early-stage health tech and biotech companies. The Seismic acquisition establishes the Emerging Innovation Group within Spectrum, a new offering that expands the agency's capabilities to deliver at all points of a company and product lifecycle. "We're delighted to welcome Seismic's incredible talent and expertise to the Spectrum team," says Jonathan Wilson, Owner and CEO of Spectrum. "For the past several years, we've worked to strategically diversify talent and capabilities within our agency, to keep pace with client needs in a rapidly evolving industry—including the burgeoning biotech and health tech sectors. With today's acquisition, we're now able to broaden the scope of clients we support, bringing a flexible model and approach to service both early-stage and start-up clients as well as those who are more established." This new venture brings seasoned leaders with extensive experience and current business in emerging innovation and health technology to the Spectrum team, including Seismic CEO, Lisa Rodriguez, who will serve as the President of the Emerging Innovation Group within Spectrum and will play a lead role within the company's existing Health Tech practice. "Becoming a part of the Spectrum organization strengthens Seismic's connection to clients who are growing, expanding and advancing innovation in the health tech and life science sectors. Now more than ever before, emerging companies require end-to-end, global capabilities to reach their hypergrowth goals—Spectrum is the perfect place to make that happen. Our new home provides a dynamic and vibrant extension of our services where we can evolve with our client partners throughout their lifecycle." Seismic CEO Lisa Rodriguez Also joining the Spectrum organization from Seismic are EVPs Melissa Laverty and Vikki Herrera, along with Seismic's full team of strategists, writers and earned and social media specialists. Today's announcement builds on the recently announced acquisition of SONIC Health, the first deal of its kind for Spectrum in the company's 26-year history. Financing for both acquisitions was provided by Monroe Capital. About The Seismic Collaborative The Seismic Collaborative communicates the stories of the people, products and services that transform healthcare and save lives through a range of strategy, media relations, content and social media services. The Seismic Collaborative's model rejects traditional PR agency norms, focusing instead on high-touch, deeply engaged, collaborative partnerships that are structured upon the results achieved. To learn more, visit www.teamseismic.com. About Spectrum Science Spectrum Science is an integrated marketing, communications and media agency like no other. An independent, full-service agency with end-to-end capabilities, Spectrum's team are experts in science—focused on strategic engagements with our audiences. We leverage human-centered insights, motivating creative, innovative storytelling and technology to reach audiences where they are with the content they need and want. Spectrum offers global reach as the US partner and chair of Global Health Marketing & Communications (GHMC).

Read More

MEDICAL DEVICES

Astorg Acquires Majority Interest in Avania

Avania | June 21, 2022

Avania, the preeminent, full-service global MedTech contract research organization announced that Astorg has acquired a majority stake in the company. Astorg, together with Kester Capital current investor who intends to retain a minority stake will actively support management’s plans to advance Avania’s development as a MedTech solution provider. Headquartered in the Netherlands, Avania was formed in March 2020 from the combination of five complementary businesses and started a successful journey to establish a fully integrated platform to serve sponsors worldwide in advancing medical technology products from early development to post-market ensuring customized, scalable solutions that optimize efficiencies and streamline the advancement of medical technology. Astorg brings an impressive global network of relationships in the MedTech space which will strengthen Avania’s pipeline and broaden its customer base while the capital access will help accelerate its growth, both organically and via acquisitions. “The platform we have built has positioned us ahead of our competition in the MedTech CRO space, and this deal will bring additional investment to strengthen our infrastructure, capital for acquisitions, and added support as we continue to grow Avania into the clear market leader. The largest CROs do not have the specialization that we bring, and the regional niche providers do not have the scale and reach of Avania. This unique positioning, along with the continued changes to the MedTech regulatory landscape, will allow us to push ourselves to the next era of growth.” Sapna Hornyak, president and CEO of Avania “We are extremely pleased to partner with Sapna and her team, as well as Kester, on this transaction,” said Managing Partner of Astorg Mid-Cap Edouard Pillot. “Being one of the global leaders in a profitable and fast-growing niche market, Avania squarely fits with Astorg’s investment criteria, and we are delighted to have Avania as our first Mid-Cap Healthcare deal, sitting within Astorg’s broader healthcare portfolio.” About Avania Avania is a leading, global full-service contract research organization focused on the management of clinical studies for medical technology, IVDs, biologics, and device-drug combination products internationally. Avania supports products from the first-in-human phase through the post-market phase with the same customized approach. When you need to advance your medical technology, it takes Avania. Avania’s vision is to be your trusted global partner in the evolution of your medical technology from innovation to commercialization to improving patient health and well-being. About Astorg Astorg is a leading private equity firm with over €17 billion of assets under management. We work with entrepreneurs and management teams to acquire market-leading global companies headquartered in Europe or the US, providing them with the strategic guidance, governance, and capital they need to achieve their growth goals. Astorg enjoys a distinct entrepreneurial culture, a long-term shareholder perspective, and a lean decision-making body. We have valuable industry expertise in healthcare, software, business-to-business professional services and technology-based industrial companies. Astorg has offices in London, Paris, New York, Frankfurt, Milan and Luxembourg. About Kester Capital Kester Capital is a primary buy-out specialist. Kester focuses on the healthcare, data & information and technology sectors, targeting businesses that require capital in order to unlock their potential.

Read More

Spotlight

Telehealth is transforming the way people receive health care across the United States. With recent advances in broadband coverage and affordable equipment, it is rapidly becoming integrated into primary care, specialty services, and complex health systems. However, many people are still unsure what it is, what quality of care it can provide, and how it could apply to their own health or community.

Resources